Clinical Trials Logo

Clinical Trial Summary

The aim of this study was to investigate whether NETs markers can enhance predict portal vein tumor thrombosis in patients with live cirrhosis, so as to establish a novel predictor to guide clinical decision-making.


Clinical Trial Description

Eighty-six patients with patients treated at the Affiliated Hospital of Qingdao University (China) from September 2020 to January 2021 were recruited for this study, including 14 patients with portal vein tumor thrombosis, 28 patients without portal vein tumor thrombosis and 44 patients without hepatocellular carcinoma. NETs markers (Myeloperoxidase, Neutrophil elastase, Citrate histone H3), and anti-β2 glycoprotein I were detected in plasma using capture ELISA and specific ELISA kits. T-test was performed to analyze whether there was a statistical difference between the two groups, and regression analysis was performed between NETs markers and tissue factor and anti-β2 glycoprotein I to investigate whether there was a correlation. This study without any intervention measures, will not cause harm. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05040347
Study type Observational
Source The Affiliated Hospital of Qingdao University
Contact
Status Completed
Phase
Start date August 18, 2020
Completion date February 28, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04104074 - Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis Phase 1
Recruiting NCT02290977 - Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC) Phase 2
Recruiting NCT03730675 - Irradiation Stent Placement Plus TACE for HCC and PVTT N/A
Completed NCT03108248 - ISP-TACE Versus TACE for HCC With PVTT N/A
Completed NCT04966195 - Stereotactic Body Radiotherapy Based Treatment for Hepatocellular Carcinoma With Extensive Portal Vein Tumor Thrombosis N/A
Recruiting NCT02571946 - Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis N/A
Terminated NCT03035006 - Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Phase 1/Phase 2